Q-omics provides the consensus-scored TADA2B profile across patient tissues and cancer cell-line models. TADA2B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TADA2B is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TADA2B RNA expression shows 19,563 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where TADA2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TADA2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TADA2B survival associations across molecular data types. TADA2B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TADA2B RNA expression–survival associations across cancer types. High TADA2B expression shows unfavorable associations in LUSC, but favorable associations in KIRC, BRCA, UCEC, ACC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TADA2B RNA expression.
This table summarizes TADA2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TADA2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TADA2B shows lower tumor expression in COAD, THCA, READ, LUSC and KIRC and higher tumor expression in LIHC. The COAD box plot shows higher TADA2B RNA expression in normal versus tumor tissue (log2 FC = −0.604, t-test p < 0.001).
This table shows molecular features associated with TADA2B in patient tissues and cancer cell lines. In patient samples, TADA2B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TADA2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
